Last reviewed · How we verify
MEDI4736 Evaluate MEDI4736 in MDS
At a glance
| Generic name | MEDI4736 Evaluate MEDI4736 in MDS |
|---|---|
| Also known as | durvalumab |
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes (PHASE2)
- Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI4736 Evaluate MEDI4736 in MDS CI brief — competitive landscape report
- MEDI4736 Evaluate MEDI4736 in MDS updates RSS · CI watch RSS
- MedImmune LLC portfolio CI